{
  "docId": "019de072-50fd-76be-bc50-13d10a429187",
  "docSlug": "745181b5445c8f31a0d7e29e54da559e",
  "documentTitle": "Chimerix | Results Presentation Deck | 12 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 8,
  "pageCount": 12,
  "prevPage": 7,
  "nextPage": 9,
  "slideType": "appendix_methodology",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The slide details the mouse-adapted model (MA10) and the specific dosing regimen for CMX521.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de072-50fd-76be-bc50-13d10a429187/8",
  "deckHref": "/decks/019de072-50fd-76be-bc50-13d10a429187",
  "deckJsonHref": "/decks/019de072-50fd-76be-bc50-13d10a429187.json",
  "deckAnchorHref": "/decks/019de072-50fd-76be-bc50-13d10a429187#slide-8",
  "components": [
    {
      "bbox": {
        "h": 0.338,
        "w": 0.35,
        "x": 0.628,
        "y": 0.335
      },
      "kind": "image",
      "text": "Mouse and nebulizer setup",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3165b15-dddc-4368-8384-6ae7a77319b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "Mouse-adapted SARS-CoV-2-MA10 model: Intranasal infection, Replicates lung pathology of human infection at 4-days post infection, Adjusted disease course suggests 1 day in mouse ≈ 5-7 days in human",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31d09dc1-8cfb-4fb9-ba48-900347e6419f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.079
      },
      "kind": "list",
      "text": "Clinical observations and virology outcomes",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3b196ca9-800d-4c21-879e-0e33b456e90c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.04,
        "y": 0.44
      },
      "kind": "list",
      "text": "CMX521 delivered as inhaled nebulized liquid aerosol: Simple, pH-adjusted saline formulation well-tolerated, 5 mg (dose delivered to chamber) every 8 hours from initiation to Day 4, CMX521-TP detected in 5/5 mouse lung lobes up to 8 hours after single administration of inhaled aerosolized CMX521, Minimal systemic exposure",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "995490df-17ef-4e86-bd07-ce66d405f6e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Collaboration with UNC employed a preclinical SARS-CoV-2 model",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94eaa334-6251-4db6-938b-574e2fd7e465",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "8c504b31-7c05-40d6-a292-dec783fc2753",
      "evidence": "CMX521 delivered as inhaled nebulized liquid aerosol: Simple, pH-adjusted saline formulation well-tolerated, 5 mg (dose delivered to chamber) every 8 hours from initiation to Day 4, CMX521-TP detected in 5/5",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}